APA

Shah N., Thall P. F., Fox P. S., Bashir Q., Shah J. J., Parmar S., Lin P., Kebriaei P., Nieto Y., Popat U. R., Hosing C. M., Cornelison A., Shpall E. J., Orlowski R. Z., Champlin R. E. & Qazilbash M. H. (20151120). Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. : Leukemia.

Chicago

Shah N, Thall P F, Fox P S, Bashir Q, Shah J J, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat U R, Hosing C M, Cornelison A, Shpall E J, Orlowski R Z, Champlin R E and Qazilbash M H. 20151120. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. : Leukemia.

Harvard

Shah N., Thall P. F., Fox P. S., Bashir Q., Shah J. J., Parmar S., Lin P., Kebriaei P., Nieto Y., Popat U. R., Hosing C. M., Cornelison A., Shpall E. J., Orlowski R. Z., Champlin R. E. and Qazilbash M. H. (20151120). Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. : Leukemia.

MLA

Shah N, Thall P F, Fox P S, Bashir Q, Shah J J, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat U R, Hosing C M, Cornelison A, Shpall E J, Orlowski R Z, Champlin R E and Qazilbash M H. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. : Leukemia. 20151120.